BAO PHARMA-B's stock price surged 5.02% during intraday trading on Wednesday, driven by multiple positive developments that boosted investor confidence.

The company's controlling shareholder group, led by Chairman Dr. Liu Yanjun, announced plans to increase holdings of up to 38,893,900 H shares through open market transactions within three months, signaling strong internal confidence in the company's long-term value. Currently, the controlling shareholder group holds approximately 40.57% of the issued shares.

Additionally, the company received approval from China's National Medical Products Administration for the commercial launch of its injectable human hyaluronidase, adding a new commercialized product to its pipeline and strengthening future earnings expectations. The shareholders' general meeting also approved a share repurchase authorization, with the company confirming that repurchase funds are legally compliant and will not affect normal operations.